Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Godfrey, L. (Lisa); Yamada-Fowler, N. (Naomi); Smith, L.; Thornalley, Paul J.; Rabbani, Naila (2014)
Publisher: Nature Publishing Group
Languages: English
Types: Article
Subjects: RC

Classified by OpenAIRE into

mesheuropmc: lipids (amino acids, peptides, and proteins), nutritional and metabolic diseases
Background/Objectives: Decreased plasma concentration of high-density lipoprotein cholesterol (HDL-C) is a risk factor linked to increased risk of cardiovascular disease (CVD). Decreased anti-atherogenic properties of HDL are also implicated in increased CVD risk. The cause is unknown but has been linked to impaired glucose tolerance. The aim of this study was to quantify the modification of HDL by methylglyoxal and related dicarbonyls in healthy people and patients with type 2 diabetes characterise structural, functional and physiological consequences of the modification and predict the importance in high CVD risk groups.\ud Subjects/Methods: Major fractions of HDL, HDL2 and HDL3 were isolated from healthy human subjects and patients with type 2 diabetes and fractions modified by methylglyoxal and related dicarbonyl metabolites quantified. HDL2 and HDL3 were glycated by methylglyoxal to minimum extent in vitro and molecular, functional and physiological characteristics were determined. A one-compartment model of HDL plasma clearance was produced including formation and clearance of dicarbonyl-modified HDL.\ud Results: HDL modified by methylglyoxal and related dicarbonyl metabolites accounted for 2.6% HDL and increased to 4.5% in patients with type 2 diabetes mellitus (T2DM). HDL2 and HDL3 were modified by methylglyoxal to similar extents in vitro. Methylglyoxal modification induced re-structuring of the HDL particles, decreasing stability and plasma half-life in vivo. It occurred at sites of apolipoprotein A-1 in HDL linked to membrane fusion, intramolecular bonding and ligand binding. Kinetic modelling of methylglyoxal modification of HDL predicted a negative correlation of plasma HDL-C with methylglyoxal-modified HDL. This was validated clinically. It also predicted that dicarbonyl modification produces 2–6% decrease in total plasma HDL and 5–13% decrease in functional HDL clinically.\ud Conclusions: These results suggest that methylglyoxal modification of HDL accelerates its degradation and impairs its functionality in vivo, likely contributing to increased risk of CVD—particularly in high CVD risk groups.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1 Sarwar N, Gao P, Seshasai SRK, Gobin R, Kaptoge S, Di Angelantonio E et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-2222.
    • 2 Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050-1065.
    • 3 Haase CL, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Populationbased resequencing of APOA1 in 10,330 individuals: spectrum of genetic variation, phenotype, and comparison with extreme phenotype approach. PLoS Genet 2012; 8: e1003063.
    • 4 van der Steeg WA, Holme I, Boekholdt SM, Larsen M. L, Lindahl C, Stroes ESG et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk Studies. J Am Coll Cardiol 2008; 51: 634-642.
    • 5 Rader DJ, Tall AR. The not-so-simple HDL story Is it time to revise the HDL cholesterol hypothesis? Nat Med 2012; 18: 1344-1346.
    • 6 Xue M, Rabbani N, Thornalley PJ. Glyoxalase in ageing. Semin Cell Dev Biol 2011; 22: 293-301.
    • 7 Beisswenger PJ, Wood ME, Howell SK, Touchette AD, O'Dell RM, Szwergold BS. α-Oxoaldehydes increase in the postprandial period and reflect the degree of hyperglycaemia. Diabetes Care 2001; 24: 726-732.
    • 8 McLellan AC, Thornalley PJ, Benn J, Sonksen PH. The glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci 1994; 87: 21-29.
    • 9 Rabbani N, Thornalley PJ. Glyoxalase in diabetes, obesity and related disorders. Semin Cell Dev Biol 2011; 22: 309-317.
    • 10 Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Hanssen KF et al. Increased serum levels of methylglyoxal-derived hydroimidazolone-AGE are associated with increased cardiovascular disease mortality in nondiabetic women. Atherosclerosis 2009; 205: 590-594.
    • 11 Ahmed N, Babaei-Jadidi R, Howell SK, Beisswenger PJ, Thornalley PJ. Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 2005; 48: 1590-1603.
    • 12 Agalou S, Ahmed N, Babaei-Jadidi R, Dawnay A, Thornalley PJ. Profound mishandling of protein glycation degradation products in uremia and dialysis. J Am Soc Nephrol 2005; 16: 1471-1485.
    • 13 Rabbani N, Thornalley PJ. Methylglyoxal, glyoxalase 1 and the dicarbonyl proteome. Amino Acids 2012; 42: 1133-1142.
    • 14 McPherson PAC, Young IS, McKibben B, McEneny J. High density lipoprotein subfractions: isolation, composition, and their duplicitous role in oxidation. J Lipid Res 2007; 48: 86-95.
    • 15 Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345-1353.
    • 16 Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 1981; 665: 408-419.
    • 17 Cavigiolio G, Shao B, Geier EG, Ren G, Heinecke JW, Oda MN. The Interplay between Size, morphology, stability, and functionality of high-density lipoprotein subclasses. Biochemistry 2008; 47: 4770-4779.
    • 18 Rabbani N, Varma Chittari M, Bodmer CW, Zehnder D, Ceriello A, Thornalley PJ. Increased glycation and oxidative damage to apolipoprotein B100 of LDL in patients with type 2 diabetes and effect of metformin. Diabetes 2010; 59: 1038-1045.
    • 19 Tall A, Granot E, Brocia R, Tabas I, Hesler C, Williams K et al. Accelerated transfer of cholesteryl esters in dyslipidemic plasma - role of cholesteryl ester transfer protein. J Clin Invest 1987; 79: 1217-1225.
    • 20 Kunitake ST, Mendel CM, Hennessy LK. Interconversion between apolipoprotein A-I-containing lipoproteins of pre-beta and alpha electrophoretic mobilities. J Lipid Res 1992; 33: 1807-1816.
    • 21 Connolly DT, Heuvelman D, Glenn K. Inactivation of cholesteryl ester transfer protein by cysteine modification. Biochem Biophys Res Commun 1996; 223: 42-47.
    • 22 Hope HR, Heuvelman D, Duffin K, Smith C, Zablocki J, Schilling R et al. Inhibition of cholesteryl ester transfer protein by substituted dithiobisnicotinic acid dimethyl ester: involvement of a critical cysteine. J Lipid Res 2000; 41: 1604-1614.
    • 23 Rabbani N, Godfrey L, Xue M, Shaheen F, Geoffrion M, Milne R et al. Conversion of low density lipoprotein to the pro-atherogenic form by methylglyoxal with increased arterial proteoglycan binding and aortal retention. Diabetes 2011; 60: 1973-1980.
    • 24 Ahmed N, Dobler D, Dean M, Thornalley PJ. Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity. J Biol Chem 2005; 280: 5724-5732.
    • 25 Silva RA, Huang R, Morris J, Fang J, Gracheva EO, Ren G et al. Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes. Proc Natl Acad Sci USA 2008; 105: 12176-12181.
    • 26 Segrest JP, Jones MK, Klon AE, Sheldahl CJ, Hellinger M, De Loof H et al. A detailed molecular belt model for apolipoprotein A-I in discoidal high density lipoprotein. J Biol Chem 1999; 274: 31755-31758.
    • 27 Hoops S, Sahle S, Gauges R, Lee C, Pahle J, Simus N et al. COPASI - COmplex PAthway SImulator. Bioinformatics 2006; 22: 3067-3074.
    • 28 Frenais R, Ouguerram K, Maugeais C, Mahot P, Maugere P, Krempf M et al. High density lipoprotein apolipoprotein Al kinetics in NIDDM: a stable isotope study. Diabetologia 1997; 40: 578-583.
    • 29 Anderson DW, Nichols AV, Forte TM, Lindgren FT. Particle distribution of human serum high density lipoproteins. Biochim Biophys Acta 1977; 493: 55-68.
    • 30 Arsenault BJ, Lemieux I, Despres JP, Gagnon P, Wareham NJ, Stroes ESG et al. HDL particle size and the risk of coronary heart disease in apparently healthy men and women: The EPIC-Norfolk prospective population study. Atherosclerosis 2009; 206: 276-281.
    • 31 Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circulation Research 2005; 96: 1221-1232.
    • 32 Webb NR, Connell PM, Graf GA, Smart EJ, de Villiers WJS, de Beer FC et al. SR-BII, an isoform of the scavenger receptor BI containing an alternate cytoplasmic tail, mediates lipid transfer between high density lipoprotein and cells. J Biol Chem 1998; 273: 15241-15248.
    • 33 Guendouzi K, Collet X, Perret B, Chap H, Barbaras R. Remnant high density lipoprotein2 particles produced by hepatic lipase display high-affinity binding and increased endocytosis into a human hepatoma cell line (HEPG2). Biochemistry 1998; 37: 14974-14980.
    • 34 Lewis GF, Lamarche B, Uffelman KD, Heatherington AC, Honig MA, Szeto LW et al. Clearance of postprandial and lipolytically modified human HDL in rabbits and rats. J Lipid Res 1997; 38: 1771-1778.
    • 35 Eisenberg S, Windmueller HG, Levy RI. Metabolic fate of rat and human lipoprotein apoproteins in the rat. J Lipid Res 1973; 14: 446-458.
    • 36 Huang R, Silva RAG, Jerome WG, Kontush A, Chapman MJ, Curtiss LK et al. Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol 2011; 18: 416-422.
    • 37 Mei X, Atkinson D. Crystal structure of C-terminal truncated apolipoprotein A-I reveals the assembly of high density lipoprotein (HDL) by dimerization. J Biol Chem 2011; 286: 38570-38582.
    • 38 Thompson PD, Cullinane EM, Sady SP, Flynn MM, Bernier DN, Kantor MA et al. Modest changes in high-density lipoprotein concentration and metabolism with prolonged exercise training. Circulation 1988; 78: 25-34.
    • 39 Rabbani N, Thornalley PJ. Dicarbonyls (glyoxal, methylglyoxal, and 3-deoxyglucosone). In: Niwa T (ed.), Uremic Toxins. John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2012. pp 177-192.
    • 40 Annema W, von Eckardstein A. High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis. Circ J 2013; 77: 2432-2448.
    • 41 Kurosaki Y, Tsukushi T, Munekata S, Akahoshi T, Moriya T, Ogawa Z. Semiquantitative analysis of apolipoprotein A-I modified by advanced glycation end products in diabetes mellitus. J Clin Lab Analysis 2013; 27: 231-236.
    • 42 Brinton EA, Eisenberg S, Breslow JL. Human HDL cholesterol levels are determined by ApoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle-size. Arterioscler Thromb 1994; 14: 707-720.
    • 43 Krikken JA, Gansevoort RT, Dullaart RPFon behalf of the PSG. Lower HDL-C and apolipoprotein A-I are related to higher glomerular filtration rate in subjects without kidney disease. J Lipid Res 2010; 51: 1982-1990.
    • 44 Dhar A, Dhar I, Jiang B, Desai KM, Wu L. Chronic methylglyoxal infusion by minipump causes pancreatic beta-cell dysfunction and induces type 2 diabetes in Sprague-Dawley rats. Diabetes 2011; 60: 899-908.
    • 45 Bashtovyy D, Jones MK, Anantharamaiah GM, Segrest JP. Sequence conservation of apolipoprotein A-I affords novel insights into HDL structure-function. J Lipid Res 2011; 52: 435-450.
    • 46 de Beer MC, Durbin DM, Cai L, Jonas A, de Beer FC, van der Westhuyzen DR. Apolipoprotein A-I conformation markedly influences HDL interaction with scavenger receptor BI. J Lipid Res 2001; 42: 309-313.
    • 47 Roosbeek S, Vanloo B, Duverger N, Caster H, Breyne J, De Beun I et al. Three arginine residues in apolipoprotein A-I are critical for activation of lecithin: cholesterol acyltransferase. J Lipid Res 2001; 42: 31-40.
    • 48 Shao BH, Cavigiolio G, Brot N, Oda MN, Heinecke JW. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-1. Proc Natl Acad Sci USA 2008; 105: 12224-12229.
    • 49 Shao BH, Pennathur S, Heinecke JW. Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions. J Biol Chem 2012; 287: 6375-6386.
    • 50 Hedrick CC, Thorpe SR, Fu MX, Harper CM, Yoo J, Kim SM et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000; 43: 312-320.
    • 51 Calvo C, Ulloa N, Campos M, Verdugo C, Ayrault-Jarrier M. The preferential site of non-enzymatic glycation of human apolipoprotein A-I in vivo. Clin Chim Acta 1993; 217: 193-198.
    • 52 Calvo C, Talussot C, Ponsin G, Berthezene F. Non enzymatic glycation of apolipoprotein A-I. Effects on its self-association and lipid binding properties. Biochem Biophys Res Commun 1988; 153: 1060-1067.
    • 53 Jones MK, Gu F, Catte A, Li L, Segrest JP. "Sticky" and "promiscuous", the yin and yang of apolipoprotein A-I termini in discoidal high-density lipoproteins: a combined computational-experimental approach. Biochemistry 2011; 50: 2249-2263.
    • 54 Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ, Charlton F et al. The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia 2007; 50: 643-653.
    • 55 Zhang L, Yan F, Zhang S, Lei D, Charles M. A, Cavigiolio G et al. Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein. Nat Chem Biol 2012; 8: 342-349.
    • 56 Ranalletta M, Bierilo KK, Chen Y, Milot D, Chen Q, Tung E et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J Lipid Res 2010; 51: 2739-2752.
    • 57 Rizzo M, Otvos JD, Nikolic D, Montalto G, Toth PP, Banach M. Subfractions and subpopulations of HDL: an update. Curr Med Chem 2014; 21: 2881-2891.
    • 58 Okubo K, Ikewaki K, Sakai S, Tada N, Kawaguchi Y, Mochizuki S. Abnormal HDL apolipoprotein A-I and A-II kinetics in hemodialysis patients: A stable isotope study. J Am Soc Nephrol 2004; 15: 1008-1015.
    • 59 Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
    • 60 Berthold HK, Rizzo M, Spenrath N, Montalto G, Krone W, Gouni-Berthold I. Effects of lipid-lowering drugs on high-density lipoprotein subclasses in healthy men-a randomized trial. PLoS One 2014; 9: e91565.
  • Inferred research data

    The results below are discovered through our pilot algorithms. Let us know how we are doing!

    Title Trust
  • Discovered through pilot similarity algorithms. Send us your feedback.

Share - Bookmark

Cite this article